Compare Citius Pharmaceuticals Inc (CTXR) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Shell PLC — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while Shell PLC trades at $90.22 (market cap $250.44B). The key difference: Shell PLC is far larger — about 12515.7× Citius Pharmaceuticals Inc's market cap, and Shell PLC pays a 3.45% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SHEL | |
|---|---|---|
Market Cap | $20.01M | $250.44B |
Sector | Health | Energy |
52-Week High | $1.82 | $94.15 |
52-Week Low | $0.48 | $70.31 |
Enterprise Value | $16.23M | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Shell (SHEL) trades at $90.15, up 0.22% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.60. Recent Q2 2026 earnings beat estimates with EPS of $3.52 versus $3.23 expected, driven by higher oil prices and strong operational performance. The company maintains solid profitability with a net income margin of 8.76% and ROE of 14.35%, while cash flow from operations reached $42.86B in 2025.
Outlook is positive due to undervaluation (P/E of 10.01), rising oil prices, and strategic asset sales, but risks include commodity volatility and geopolitical tensions affecting energy markets. With 69% of analysts rating it Buy and institutional support, SHEL offers growth potential, though investors should monitor debt levels and global energy demand shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
